Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor β correlates with the survival of breast cancer patients

Alexei Y. Savinov, Albert G. Remacle, Vladislav S. Golubkov, Maryla Krajewska, Susan Kennedy, Michael J. Duffy, Dmitri Rozanov, Stan Krajewski, Alex Y. Strongin

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Estrogens have many cellular functions, including their interactions with estrogen receptors α and β (ERα and ERβ). Earlier, we determined that the estrogen-ER complex stimulates the transcriptional activity of the matrix metalloproteinase 26 (MMP-26) gene promoter. We then determined that ERβ is susceptible to MMP-26 proteolysis whereas ERα is resistant to the protease. MMP-26 targets the NH2-terminal region of ERβ coding for the divergent NH2-terminal A/B domain that is responsible for the ligand-independent transactivation function. As a result, MMP-26 proteolysis generates the COOH-terminal fragments of ERβ. Immunohistochemical analysis of tissue microarrays derived from 121 cancer patients corroborated these data and revealed an inverse correlation between the ERα-dependent expression of MMP-26 and the levels of the intact ERβ in breast carcinomas. MMP-26 is not expressed in normal mammary epithelium. The levels of MMP-26 are strongly up-regulated in ductal carcinoma in situ (DCIS). In the course of further disease progression through stages I to III, the expression of MMP-26 decreases. In contrast to many tumor-promoting MMPs, the expression of MMP-26 in DCIS correlated with a longer patient survival. Our data suggest the existence of an MMP-26-mediated intracellular pathway that targets ERβ and that MMP-26, a novel and valuable cancer marker, contributes favorably to the survival of the ERα/β-positive cohort of breast cancer patients.

Original languageEnglish (US)
Pages (from-to)2716-2724
Number of pages9
JournalCancer Research
Volume66
Issue number5
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Matrix Metalloproteinases
Estrogen Receptors
Proteolysis
Breast Neoplasms
Survival
Carcinoma, Intraductal, Noninfiltrating
Estrogens
Tissue Array Analysis
Neoplasms
Transcriptional Activation
Disease Progression
Breast
Peptide Hydrolases
Epithelium
Ligands

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Savinov, A. Y., Remacle, A. G., Golubkov, V. S., Krajewska, M., Kennedy, S., Duffy, M. J., ... Strongin, A. Y. (2006). Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor β correlates with the survival of breast cancer patients. Cancer Research, 66(5), 2716-2724. https://doi.org/10.1158/0008-5472.CAN-05-3592

Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor β correlates with the survival of breast cancer patients. / Savinov, Alexei Y.; Remacle, Albert G.; Golubkov, Vladislav S.; Krajewska, Maryla; Kennedy, Susan; Duffy, Michael J.; Rozanov, Dmitri; Krajewski, Stan; Strongin, Alex Y.

In: Cancer Research, Vol. 66, No. 5, 01.03.2006, p. 2716-2724.

Research output: Contribution to journalArticle

Savinov, AY, Remacle, AG, Golubkov, VS, Krajewska, M, Kennedy, S, Duffy, MJ, Rozanov, D, Krajewski, S & Strongin, AY 2006, 'Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor β correlates with the survival of breast cancer patients', Cancer Research, vol. 66, no. 5, pp. 2716-2724. https://doi.org/10.1158/0008-5472.CAN-05-3592
Savinov, Alexei Y. ; Remacle, Albert G. ; Golubkov, Vladislav S. ; Krajewska, Maryla ; Kennedy, Susan ; Duffy, Michael J. ; Rozanov, Dmitri ; Krajewski, Stan ; Strongin, Alex Y. / Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor β correlates with the survival of breast cancer patients. In: Cancer Research. 2006 ; Vol. 66, No. 5. pp. 2716-2724.
@article{836d9bce7bfe422c80124f85862c99bb,
title = "Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor β correlates with the survival of breast cancer patients",
abstract = "Estrogens have many cellular functions, including their interactions with estrogen receptors α and β (ERα and ERβ). Earlier, we determined that the estrogen-ER complex stimulates the transcriptional activity of the matrix metalloproteinase 26 (MMP-26) gene promoter. We then determined that ERβ is susceptible to MMP-26 proteolysis whereas ERα is resistant to the protease. MMP-26 targets the NH2-terminal region of ERβ coding for the divergent NH2-terminal A/B domain that is responsible for the ligand-independent transactivation function. As a result, MMP-26 proteolysis generates the COOH-terminal fragments of ERβ. Immunohistochemical analysis of tissue microarrays derived from 121 cancer patients corroborated these data and revealed an inverse correlation between the ERα-dependent expression of MMP-26 and the levels of the intact ERβ in breast carcinomas. MMP-26 is not expressed in normal mammary epithelium. The levels of MMP-26 are strongly up-regulated in ductal carcinoma in situ (DCIS). In the course of further disease progression through stages I to III, the expression of MMP-26 decreases. In contrast to many tumor-promoting MMPs, the expression of MMP-26 in DCIS correlated with a longer patient survival. Our data suggest the existence of an MMP-26-mediated intracellular pathway that targets ERβ and that MMP-26, a novel and valuable cancer marker, contributes favorably to the survival of the ERα/β-positive cohort of breast cancer patients.",
author = "Savinov, {Alexei Y.} and Remacle, {Albert G.} and Golubkov, {Vladislav S.} and Maryla Krajewska and Susan Kennedy and Duffy, {Michael J.} and Dmitri Rozanov and Stan Krajewski and Strongin, {Alex Y.}",
year = "2006",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-05-3592",
language = "English (US)",
volume = "66",
pages = "2716--2724",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor β correlates with the survival of breast cancer patients

AU - Savinov, Alexei Y.

AU - Remacle, Albert G.

AU - Golubkov, Vladislav S.

AU - Krajewska, Maryla

AU - Kennedy, Susan

AU - Duffy, Michael J.

AU - Rozanov, Dmitri

AU - Krajewski, Stan

AU - Strongin, Alex Y.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Estrogens have many cellular functions, including their interactions with estrogen receptors α and β (ERα and ERβ). Earlier, we determined that the estrogen-ER complex stimulates the transcriptional activity of the matrix metalloproteinase 26 (MMP-26) gene promoter. We then determined that ERβ is susceptible to MMP-26 proteolysis whereas ERα is resistant to the protease. MMP-26 targets the NH2-terminal region of ERβ coding for the divergent NH2-terminal A/B domain that is responsible for the ligand-independent transactivation function. As a result, MMP-26 proteolysis generates the COOH-terminal fragments of ERβ. Immunohistochemical analysis of tissue microarrays derived from 121 cancer patients corroborated these data and revealed an inverse correlation between the ERα-dependent expression of MMP-26 and the levels of the intact ERβ in breast carcinomas. MMP-26 is not expressed in normal mammary epithelium. The levels of MMP-26 are strongly up-regulated in ductal carcinoma in situ (DCIS). In the course of further disease progression through stages I to III, the expression of MMP-26 decreases. In contrast to many tumor-promoting MMPs, the expression of MMP-26 in DCIS correlated with a longer patient survival. Our data suggest the existence of an MMP-26-mediated intracellular pathway that targets ERβ and that MMP-26, a novel and valuable cancer marker, contributes favorably to the survival of the ERα/β-positive cohort of breast cancer patients.

AB - Estrogens have many cellular functions, including their interactions with estrogen receptors α and β (ERα and ERβ). Earlier, we determined that the estrogen-ER complex stimulates the transcriptional activity of the matrix metalloproteinase 26 (MMP-26) gene promoter. We then determined that ERβ is susceptible to MMP-26 proteolysis whereas ERα is resistant to the protease. MMP-26 targets the NH2-terminal region of ERβ coding for the divergent NH2-terminal A/B domain that is responsible for the ligand-independent transactivation function. As a result, MMP-26 proteolysis generates the COOH-terminal fragments of ERβ. Immunohistochemical analysis of tissue microarrays derived from 121 cancer patients corroborated these data and revealed an inverse correlation between the ERα-dependent expression of MMP-26 and the levels of the intact ERβ in breast carcinomas. MMP-26 is not expressed in normal mammary epithelium. The levels of MMP-26 are strongly up-regulated in ductal carcinoma in situ (DCIS). In the course of further disease progression through stages I to III, the expression of MMP-26 decreases. In contrast to many tumor-promoting MMPs, the expression of MMP-26 in DCIS correlated with a longer patient survival. Our data suggest the existence of an MMP-26-mediated intracellular pathway that targets ERβ and that MMP-26, a novel and valuable cancer marker, contributes favorably to the survival of the ERα/β-positive cohort of breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=33645046096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645046096&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-3592

DO - 10.1158/0008-5472.CAN-05-3592

M3 - Article

VL - 66

SP - 2716

EP - 2724

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 5

ER -